Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $89.90

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received a consensus rating of “Buy” from the thirteen ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $89.90.

Several brokerages have weighed in on JANX. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Stifel Nicolaus raised their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Scotiabank raised their price objective on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a research note on Wednesday, December 4th. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Finally, Leerink Partners raised their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd.

Janux Therapeutics Price Performance

Shares of JANX stock opened at $37.17 on Friday. The firm has a market cap of $1.95 billion, a PE ratio of -31.77 and a beta of 3.16. The company has a 50-day moving average of $49.36 and a two-hundred day moving average of $48.07. Janux Therapeutics has a 1-year low of $7.90 and a 1-year high of $71.71.

Insider Activity

In related news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total value of $140,994.86. Following the transaction, the insider now directly owns 82,139 shares in the company, valued at $3,473,658.31. This trade represents a 3.90 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO David Alan Campbell sold 5,000 shares of Janux Therapeutics stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief executive officer now owns 293,054 shares in the company, valued at approximately $17,583,240. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 86,668 shares of company stock valued at $4,872,515 in the last ninety days. 29.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC boosted its position in shares of Janux Therapeutics by 10.8% during the 4th quarter. FMR LLC now owns 8,669,941 shares of the company’s stock worth $464,189,000 after purchasing an additional 845,266 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Janux Therapeutics by 40.0% during the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after purchasing an additional 721,563 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Janux Therapeutics by 3,592.9% during the 4th quarter. Wellington Management Group LLP now owns 535,396 shares of the company’s stock worth $28,665,000 after purchasing an additional 520,898 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Janux Therapeutics by 2,519.6% during the 4th quarter. Franklin Resources Inc. now owns 497,287 shares of the company’s stock worth $26,625,000 after purchasing an additional 478,304 shares in the last quarter. Finally, Pictet Asset Management Holding SA purchased a new stake in shares of Janux Therapeutics during the 4th quarter worth $20,602,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.